NCT07242703

Brief Summary

This study aims to assess the efficacy of narrow-band ultraviolet B (NB-UVB) phototherapy as a standalone treatment in patients with resistant and recurrent tinea. To evaluate the clinical and mycological improvement in response to NB-UVB therapy compared to standard anti-fungal treatment alone.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 17, 2025

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 21, 2025

Completed
10 days until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

November 21, 2025

Status Verified

November 1, 2025

Enrollment Period

4 months

First QC Date

November 17, 2025

Last Update Submit

November 17, 2025

Conditions

Fungal Resistance

Outcome Measures

Primary Outcomes (1)

  • Dermatophytosis Severity Score (DSS)

    8 weeks

Study Arms (2)

NBUVB

EXPERIMENTAL

Type of phototherapy

Device: NBUVB

Medical treatment

ACTIVE COMPARATOR

combined oral itraconazole and terbinafine.

Drug: Itraconazole + terbinafine

Interventions

NBUVBDEVICE

Phototherapy device

NBUVB
Itraconazole + terbinafineDRUG

Antifungal drugs

Medical treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged ≥18 years.
  • Both sexes.
  • Clinical diagnosis of tinea corporis or cruris.
  • Failure of ≥4 weeks of systemic antifungal therapy (e.g., terbinafine or itraconazole).
  • No antifungal (topical or systemic) or corticosteroid treatment in the 2 weeks preceding enrollment.
  • Recurrent infection (≥2 relapses in the past 6 months)
  • Positive KOH microscopy and culture at baseline

You may not qualify if:

  • Photosensitivity disorders or photosensitizing medications.
  • Xeroderma pigmentosa, LE or other photosensitive dermatoses. dermatomyositis.
  • Other skin conditions (psoriasis, eczema, etc.).
  • Known autoimmune diseases, immunosuppression, or coagulopathies..

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

ItraconazoleTerbinafine

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPiperazinesNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Hagar El Sayed Abd El Ghani Anter

Study Record Dates

First Submitted

November 17, 2025

First Posted

November 21, 2025

Study Start

December 1, 2025

Primary Completion

April 1, 2026

Study Completion

May 1, 2026

Last Updated

November 21, 2025

Record last verified: 2025-11